Capricor soars on Phase 3 DMD data as analysts boost expectations
Capricor stock skyrocketed over 500% intraday after strong Phase 3 data for its Duchenne muscular dystrophy therapy, ending the session up 371% at an eight-year high. Analysts raised targets and expect potential approval by mid-2026. Retail traders also remain bullish, seeing long-term promise as the therapy aims to address both muscle decline and heart complications.